Moderna's Strong Q3 Performance and Promising Pipeline Secure Buy Rating
BofA Securities Initiates Moderna(MRNA.US) With Hold Rating, Announces Target Price $110
Jefferies Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $120
Morgan Stanley Maintains Moderna(MRNA.US) With Hold Rating, Raises Target Price to $94
Brookline Capital Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $310
Street Calls of the Week: Moderna Upgraded, Downgrade for Hershey
Moderna Price Target Announced at $82.00/Share by HSBC
Moderna Analyst Ratings
HSBC Upgrades Moderna(MRNA.US) to Hold Rating, Cuts Target Price to $82
Piper Sandler Maintains Moderna(MRNA.US) With Buy Rating, Maintains Target Price $157
Redburn Atlantic Adjusts Moderna Price Target to $102 From $117
Argus Research Maintains Moderna(MRNA.US) With Buy Rating
Argus Research Adjusts Moderna Price Target to $105 From $150, Buy Rating Maintained
J.P. Morgan Maintains Moderna(MRNA.US) With Hold Rating, Raises Target Price to $88
Evercore Maintains Moderna(MRNA.US) With Hold Rating, Maintains Target Price $105
Moderna Analyst Ratings
JPMorgan Adjusts Price Target on Moderna to $88 From $96, Maintains Neutral Rating
Analyst Maintains Sell Rating on Moderna Amid Revenue Guidance Downgrade and Competitive Challenges
Deutsche Bank Upgrades Moderna to Hold From Sell, Adjusts Price Target to $80 From $85
Moderna Analyst Ratings